Biolinerx Ltdis A Biopharmaceutical Company Based In Modi Inisraelfocused On Developing And Commercializing Innovative Therapeutics For Oncology And Rare Diseasesfounded In 2003The Company Is Publicly Traded On The Nasdaq Capital Market And The Tel Aviv Stock Exchange Under The Ticker Symbol Blrxbiolinerx Specializes In Drug Developmentoffering A Comprehensive Range Of Services From Early Stage Research To Clinical Trials And Commercialization The Company S Product Pipeline Includes Aphexdamotixafortide Which Is In Various Stages Of Clinical Trials For Conditions Such As Sickle Cell Disease And Pancreatic Cancerand Has Received Fda Approval For Multiple Myelomaanother Productbl 5010Is Designed For The Non Surgical Removal Of Skin Lesionsbiolinerx Aims To Provide Access To Its Therapies For Patients In Needparticularly Those Facing Specific Cancers And Rare Diseasesand Collaborates With Partners In The Biotech And Pharmaceutical Sectors To Advance Its Drug Candidates
